Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M08D1 in Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
NCT07818486Phase 2Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M08D1 in nasopharyngeal carcinoma (NPC), solid tumor, sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BL-M08D1
03
Conditions
nasopharyngeal carcinoma (NPC)solid tumor
Beyond the preview
Go deeper on NCT07818486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818486.